Akrimax Pharmaceuticals has introduced NitroMist (Nitroglycerin Lingual Aerosol) 400mcg/spray indicated for acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery disease. NitroMist provides nitroglycerin in a rapidly absorbed, mentholated spray formulation designed for use on or under the tongue. NitroMist is available in a fully sealed aerosol delivery system and has a shelf life of 36 months. NitroMist does not contain ethyl alcohol.

Wayne Anderson, Akrimax’ president and chief executive officer, said, “Akrimax is committed to providing health care providers and their patients with therapies that can make an important difference in the lives of patients. We believe NitroMist is an excellent example of this. NitroMist is the second new product that Akrimax has brought to market in the past year. Akrimax also has expanded its sales force by a third in order to educate health care providers about NitroMist and its other promoted brands, Tirosint and Inderal LA.”


Click here to learn more about Akrimax.